A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

• Status: RECRUITING
• Trial end date: 2030-05-18

Summary

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

• Phase: PHASE3

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: 130-nm albumin-bound paclitaxel; Albumin-Bound Paclitaxel; Carboplatin; Gemcitabine; Paclitaxel; pembrolizumab